CMA 2023 Pre-budget Submission to the House of Commons Standing Committee on Finance
https://policybase.cma.ca/link/policy14490

POLICY TYPE
Parliamentary submission

DATE
2022-10-06

TOPICS
Health systems, system funding and performance
Health human resources
Population health, health equity, public health

Documents
CMA Letter to the Council of the Federation regarding the Council of the Federation meeting and Canada’s health funding priorities (health workforce, primary care, labour mobility)
https://policybase.cma.ca/link/policy14486

POLICY TYPE
Parliamentary submission

DATE
2022-06-22

TOPICS
Health systems, system funding and performance
Health human resources

Documents
Appearance before the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities

https://policybase.cma.ca/link/policy14472

POLICY TYPE
Parliamentary submission

DATE
2022-03-28

TOPICS
Health human resources
Health systems, system funding and performance

Documents

Appearance before the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities

Dr. Kathleen Serri
President of the Canadian Medical Association
March 28, 2022

Check legal text delivery.
Federal Policy Options to Advance Pan-Canadian Licensure
https://policybase.cma.ca/link/policy14471

POLICY TYPE
Parliamentary submission

DATE
2022-02-22

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents
Study on Canada’s Health Workforce

https://policybase.cma.ca/link/policy14469

POLICY TYPE
Parliamentary submission

DATE
2022-02-16

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents

Appearance before the House of Commons Standing Committee on Health:

Study on Canada’s Health Workforce

[Dr. Erika James]
President of the Canadian Medical Association

February 15, 2022
Draft against delivery
Recommendations for federal action to address Canada’s health care crisis
https://policybase.cma.ca/link/policy14468

POLICY TYPE  Parliamentary submission
DATE  2022-02-15
TOPICS  Health systems, system funding and performance
          Health human resources
          Ethics and medical professionalism

Documents

CMA submission
Recommendations for federal action to address
Canada’s health care crisis
Submission to the House of Commons
Standing Committee on Finance
March 13, 2022
## Study on Bill S-209, An Act respecting Pandemic Observance Day

https://policybase.cma.ca/link/policy14467

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2022-02-09</td>
</tr>
</tbody>
</table>
| TOPICS            | Health care and patient safety  
Av
Ethics and medical professionalism |

### Documents

**Appearance before the Senate Standing Committee on Social Affairs, Science and Technology**

**Study on Bill S-209, An Act respecting Pandemic Observance Day**

Dr. J. K. Smith  
President of the Canadian Medical Association

February 04, 2022  
(Clarification sheet)
CMA Submission to the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities’ study of Bill C-3, An Act to amend the Criminal Code and the Canada Labour Code

https://policybase.cma.ca/link/policy14464

POLICY TYPE  Parliamentary submission
DATE  2021-12-15
TOPICS  Health care and patient safety
Ethics and medical professionalism

Documents
Mandatory COVID-19 vaccination of health care workers

https://policybase.cma.ca/link/policy14449

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health human resources
Population health, health equity, public health

Documents
Vaccine acceptance

https://policybase.cma.ca/link/policy14450

POLICY TYPE  Policy document
DATE        2021-08-21
TOPICS      Health care and patient safety
Population health, health equity, public health

Documents
Return to school during COVID-19

https://policybase.cma.ca/link/policy14452

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Interchangeability of vaccines (vaccine mixing)
https://policybase.cma.ca/link/policy14453

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Interchangeability of vaccines (vaccine mixing)

Policy position recommendation:

1. The CMA recommends the interchangeability of COVID-19 vaccines. Interchangeability is defined as the ability to substitute one vaccine for another, based on the best available evidence and clinical practice.

2. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

3. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

4. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

5. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

6. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

7. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

8. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

9. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

10. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

11. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

12. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

13. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

14. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

15. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

16. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

17. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

18. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

19. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

20. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

21. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

22. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

23. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

24. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

25. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

26. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

27. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

28. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

29. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

30. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

31. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

32. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

33. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

34. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.

35. The CMA recommends the interchangeability of COVID-19 vaccines, including the use of different brands within the same product line, such as Pfizer-BioNTech, Moderna, and Sinovac. This interchangeability is based on the available evidence and clinical practice.
Firearms Control (Update 2021)
https://policybase.cma.ca/link/policy14401

POLICY TYPE  Policy document
DATE  2021-07-15
REPLACES  Firearms control (Update 2001)
TOPICS  Population health, health equity, public health
Health care and patient safety

Documents
Consensus statement on networks for high-quality rural anesthesia, surgery, and obstetric care in Canada

https://policybase.cma.ca/link/policy14477

POLICY TYPE
Policy endorsement

DATE
2021-05-17

TOPICS
Health systems, system funding and performance
Health human resources

Documents
The Canadian Interdisciplinary Palliative Care Competency Framework
https://policybase.cma.ca/link/policy14439

POLICY TYPE
Policy endorsement

DATE
2020-12-05

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Committee Appearance – Justice and Human Rights: Bill C-7 – Amending the Criminal Code Regarding Medical Assistance in Dying
https://policybase.cma.ca/link/policy14374

POLICY TYPE
Parliamentary submission

DATE
2020-11-05

TOPICS
Health care and patient safety

Documents

Committee Appearance – Justice and Human Rights:
Bill C-7 – Amending the Criminal Code Regarding Medical Assistance in Dying
November 5, 2020
Valuing Caregivers and Recognizing Their Contribution to Quebec’s Health System
https://policybase.cma.ca/link/policy14373

POLICY TYPE  Parliamentary submission
DATE  2020-09-29
TOPICS  Health human resources
  Health systems, system funding and performance

Documents
CMA Pre-budget Submission
https://policybase.cma.ca/link/policy14259

POLICY TYPE
Parliamentary submission

DATE
2020-08-07

TOPICS
Physician practice, compensation, forms
Health information and e-health
Health care and patient safety
Health systems, system funding and performance

Documents
CMA Statement on Racism

https://policybase.cma.ca/link/policy14245

POLICY TYPE  Policy document
DATE        2020-06-02
TOPICS      Ethics and medical professionalism
Health care and patient safety

Documents
Responding to the COVID-19 pandemic: Federal measures to recognize the significant contributions of Canada’s front-line health care workers

https://policybase.cma.ca/link/policy14211

POLICY TYPE
Parliamentary submission

DATE
2020-05-28

TOPICS
Health care and patient safety